 |
 |
On 13 Jun 2003 at 15:36, Linda J Herman wrote: (in part) > This press release is very misleading (note: I am NOT blaming the > messenger (Murray); I do have an issue with Novartis though for > advertising this as "the first new drug for Parkinson's disease in over > three years." It is merely a combination of two commonly prescribed > drugs - Entacapone, which is the generic name for Comtan - a medication > people have been taking for a few years now, and Sinemet. > > Aside from the convenience of swallowing one pill instead of two at a > time, what are the benefits of Stalevo? It seems to me that taking this > combined version of tthe two would only make it more difficult to tailor > our dosages to our individual needs . > > Or am I missing something here? > Linda > Thank Heaven (& Linda) I am not being blamed! .. murray Hi Linda, janet, Charlotte, Joan, Jorge... I've been following this story for a number of years now, so I'm quite used to their expansive use of the English language in patting themselves on the back... (I didn't evn blink...) Also... my initial thoughts re: combination therapy were that (since entacapone is nothing without Sinemet) entacapone should ONLY be used in combination and if one pill is cheaper than two.... this discussion has "more" at the MGH BrainTalk... http://neuro-mancer.mgh.harvard.edu/ubb/Forum71/HTML/008556.html cheers ........ murray > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto:[log in to unmask] > In the body of the message put: signoff parkinsn * * * Murray Charters <[log in to unmask]> http://www.geocities.com/murraycharters/ ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn